Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEUROBLASTOMA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NEUROBLASTOMA DRUGS MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL NEUROBLASTOMA DRUGS MARKET FOR THALASSEMIA MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE BY MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE BY MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL NEUROBLASTOMA DRUGS MARKET , BY DRUG TYPE
14.1 OVERVIEW
14.2 CHEMOTHERAPEUTIC AGENTS
14.2.1 CISPLATIN
14.2.2 CARBOPLATIN
14.2.3 VINCRISTINE
14.2.4 ETOPOSIDE
14.2.5 CYCLOPHOSPHAMIDE
14.2.6 DOXORUBICIN
14.2.7 IFOSFAMIDE
14.2.8 OTHERS
14.3 TARGETED THERAPY DRUGS
14.3.1 ALK INHIBITORS
14.3.2 GD2 ANTIBODIES
14.4 IMMUNOTHERAPY AGENTS
14.4.1 MONOCLONAL ANTIBODIES
14.4.2 CHECKPOINT INHIBITORS
14.5 OTHERS
15 GLOBAL NEUROBLASTOMA DRUGS MARKET , BY FORMULATION
15.1 OVERVIEW
15.2 TABLETS AND CAPSULES
15.3 INJECTABLE DRUGS
15.4 OTHER
16 GLOBAL NEUROBLASTOMA DRUGS MARKET , BY TREATMENT STAGE
16.1 OVERVIEW
16.2 INDUCTION THERAPY
16.3 CONSOLIDATION THERAPY
16.4 MAINTENANCE THERAPY
16.5 OTHERS
17 GLOBAL NEUROBLASTOMA DRUGS MARKET , BY MECHANISM OF ACTION
17.1 OVERVIEW
17.2 APOPTOSIS INDUCTION
17.3 IMMUNE MODULATION
17.4 DNA DAMAGE AND REPAIR INHIBITION
17.5 ANGIOGENESIS INHIBITION
17.6 OTHERS
18 GLOBAL NEUROBLASTOMA DRUGS MARKET , BY THERAPY
18.1 OVERVIEW
18.1.1 CHEMOTHERAPY
18.1.2 BONE MARROW TRANSPLANTATION
18.1.3 RETINOID THERAPY
18.1.4 IMMUNOTHERAPY
18.1.5 OTHERS
19 GLOBAL NEUROBLASTOMA DRUGS MARKET, BY PATIENT SEGMENTS
19.1 OVERVIEW
19.2 HIGH-RISK PATIENTS
19.3 INTERMEDIATE-RISK PATIENTS
19.4 LOW-RISK PATIENTS
20 GLOBAL NEUROBLASTOMA DRUGS MARKET, BY PATIENT POPULATION
20.1 OVERVIEW
20.2 PEDIATRICS
20.3 ADULTS
20.4 GERIATRICS
21 GLOBAL NEUROBLASTOMA DRUGS MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS & CLINICS
21.3 SPECIALTY CLINICS
21.4 RESEARCH INSTITUTES
21.5 HOMECARE
21.6 OTHERS
22 GLOBAL NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAILER STORE
22.3.1 ONLINE
22.3.2 OFFLINE
22.4 OTHERS
23 GLOBAL NEUROBLASTOMA DRUGS MARKET, BY REGION
GLOBAL NEUROBLASTOMA DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 ITALY
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 SWITZERLAND
23.2.8 TURKEY
23.2.9 BELGIUM
23.2.10 NETHERLANDS
23.2.11 DENMARK
23.2.12 SWEDEN
23.2.13 POLAND
23.2.14 NORWAY
23.2.15 FINLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINES
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 EGYPT
23.5.3 BAHRAIN
23.5.4 UNITED ARAB EMIRATES
23.5.5 KUWAIT
23.5.6 OMAN
23.5.7 QATAR
23.5.8 SAUDI ARABIA
23.5.9 REST OF MEA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL NEUROBLASTOMA DRUGS MARKET, SWOT AND DBMR ANALYSIS
25 GLOBAL NEUROBLASTOMA DRUGS MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL NEUROBLASTOMA DRUGS MARKET, COMPANY PROFILE
26.1 Y-MABS THERAPEUTICS, INC.
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 EXELIXIS, INC.
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 CLARITY PHARMACEUTICALS
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 ELI LILLY AND COMPANY
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 INNERVATE RADIOPHARMACEUTICALS
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 ADAPTIMMUNE THERAPEUTICS PLC
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 PFIZER
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 ASTRAZENECA
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 JOHNSON & JOHNSON
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 SANOFI
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 BAYER AG
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 NOVARTIS AG
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 ROCHE HOLDING AG
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 MERCK & CO., INC.
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 GLAXOSMITHKLINE PLC
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 ABBVIE INC.
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 TAKEDA PHARMACEUTICAL COMPANY LIMITED
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 AMGEN INC.
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.21 GILEAD SCIENCES, INC.
26.21.1 COMPANY OVERVIEW
26.21.2 REVENUE ANALYSIS
26.21.3 GEOGRAPHIC PRESENCE
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPMENTS
26.22 CELGENE CORPORATION
26.22.1 COMPANY OVERVIEW
26.22.2 REVENUE ANALYSIS
26.22.3 GEOGRAPHIC PRESENCE
26.22.4 PRODUCT PORTFOLIO
26.22.5 RECENT DEVELOPMENTS
26.23 BIOGEN INC.
26.23.1 COMPANY OVERVIEW
26.23.2 REVENUE ANALYSIS
26.23.3 GEOGRAPHIC PRESENCE
26.23.4 PRODUCT PORTFOLIO
26.23.5 RECENT DEVELOPMENTS
26.24 ASTELLAS PHARMA INC.
26.24.1 COMPANY OVERVIEW
26.24.2 REVENUE ANALYSIS
26.24.3 GEOGRAPHIC PRESENCE
26.24.4 PRODUCT PORTFOLIO
26.24.5 RECENT DEVELOPMENTS
26.25 DAIICHI SANKYO COMPANY, LIMITED
26.25.1 COMPANY OVERVIEW
26.25.2 REVENUE ANALYSIS
26.25.3 GEOGRAPHIC PRESENCE
26.25.4 PRODUCT PORTFOLIO
26.25.5 RECENT DEVELOPMENTS
26.26 ONO PHARMACEUTICAL CO., LTD
26.26.1 COMPANY OVERVIEW
26.26.2 REVENUE ANALYSIS
26.26.3 GEOGRAPHIC PRESENCE
26.26.4 PRODUCT PORTFOLIO
26.26.5 RECENT DEVELOPMENTS
26.27 EISAI CO., LTD.
26.27.1 COMPANY OVERVIEW
26.27.2 REVENUE ANALYSIS
26.27.3 GEOGRAPHIC PRESENCE
26.27.4 PRODUCT PORTFOLIO
26.27.5 RECENT DEVELOPMENTS
26.28 UCB S.A.
26.28.1 COMPANY OVERVIEW
26.28.2 REVENUE ANALYSIS
26.28.3 GEOGRAPHIC PRESENCE
26.28.4 PRODUCT PORTFOLIO
26.28.5 RECENT DEVELOPMENTS
26.29 SHIONOGI & CO., LTD.
26.29.1 COMPANY OVERVIEW
26.29.2 REVENUE ANALYSIS
26.29.3 GEOGRAPHIC PRESENCE
26.29.4 PRODUCT PORTFOLIO
26.29.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27 RELATED REPORTS
28 QUESTIONNAIRE
29 CONCLUSION
30 ABOUT DATA BRIDGE MARKET RESEARCH
